Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement—A new target for lupus treatment
暂无分享,去创建一个
Yasser B. Ruiz-Blanco | C. Bodemer | F. Kirchhoff | S. Nisole | J. Münch | Y. Richard | D. Duffy | A. Korganow | J. Herbeuval | M. Rodero | V. Bondet | B. Bader-Meunier | P. Quartier | N. Leboulanger | B. Mayer | V. Baudouin | B. Charbit | N. Smith | Y. Dieudonné | M. Harms | B. Jahrsdörfer | Nassima Bekaddour | Y. Ruiz-Blanco | Elsa Sanchez Garcia | N. Bekaddour | Nikaïa Smith
[1] Yoshiya Tanaka,et al. Up-Regulation of TLR7-Mediated IFN-α Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus , 2018, Front. Immunol..
[2] J. Gottenberg,et al. The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials. , 2018, Autoimmunity reviews.
[3] S. Sozzani,et al. Exosome-delivered microRNAs promote IFN-α secretion by human plasmacytoid DCs via TLR7. , 2018, JCI insight.
[4] J. van Grevenynghe,et al. Sustained IFN-I Expression during Established Persistent Viral Infection: A “Bad Seed” for Protective Immunity , 2017, Viruses.
[5] Joshua B. Singer,et al. Fundamental properties of the mammalian innate immune system revealed by multispecies comparison of type I interferon responses , 2017, PLoS biology.
[6] K. Yamaji,et al. Enhanced IFN-α production is associated with increased TLR7 retention in the lysosomes of palasmacytoid dendritic cells in systemic lupus erythematosus , 2017, Arthritis Research & Therapy.
[7] F. Rieux-Laucat,et al. Detection of interferon alpha protein reveals differential levels and cellular sources in disease , 2017, The Journal of experimental medicine.
[8] Pasquale Cutolo,et al. Natural amines inhibit activation of human plasmacytoid dendritic cells through CXCR4 engagement , 2017, Nature Communications.
[9] M. Carrillo,et al. Targeting type I interferon–mediated activation restores immune function in chronic HIV infection , 2017, The Journal of clinical investigation.
[10] Zhiyuan Hu,et al. Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs , 2017, The Journal of clinical investigation.
[11] R. Sékaly,et al. The interferon paradox: can inhibiting an antiviral mechanism advance an HIV cure? , 2017, The Journal of clinical investigation.
[12] Y. Crow,et al. Type I interferon–mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview , 2016, The Journal of experimental medicine.
[13] B. L. de Groot,et al. CHARMM36m: an improved force field for folded and intrinsically disordered proteins , 2016, Nature Methods.
[14] Q. Lu,et al. The important roles of type I interferon and interferon-inducible genes in systemic lupus erythematosus. , 2016, International immunopharmacology.
[15] Hedi Peterson,et al. AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies , 2016, Cell.
[16] L. Platanias,et al. Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists , 2016, Scientific Reports.
[17] P. Vidalain,et al. An efficient method for gene silencing in human primary plasmacytoid dendritic cells: silencing of the TLR7/IRF-7 pathway as a proof of concept , 2016, Scientific Reports.
[18] Ling Lin,et al. Development of pristane induced mice model for lupus with atherosclerosis and analysis of TLR expression. , 2016, Clinical and experimental rheumatology.
[19] V. Pascual,et al. Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon production in human lupus , 2016, The Journal of experimental medicine.
[20] Virginia Pascual,et al. Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients , 2016, Cell.
[21] Nan Yan,et al. Response to Comment on “Cutting Edge: Inhibiting TBK1 by Compound II Ameliorates Autoimmune Disease in Mice” , 2016, The Journal of Immunology.
[22] Nan Yan,et al. Cutting Edge: Inhibiting TBK1 by Compound II Ameliorates Autoimmune Disease in Mice , 2015, The Journal of Immunology.
[23] John J. Irwin,et al. ZINC 15 – Ligand Discovery for Everyone , 2015, J. Chem. Inf. Model..
[24] M. Colonna,et al. The multifaceted biology of plasmacytoid dendritic cells , 2015, Nature Reviews Immunology.
[25] C. Szeto,et al. Animal Models of Interferon Signature Positive Lupus , 2015, Front. Immunol..
[26] E. Unanue,et al. Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model , 2014, The Journal of experimental medicine.
[27] V. D’Agati,et al. Genetic evidence for the role of plasmacytoid dendritic cells in systemic lupus erythematosus , 2014, The Journal of experimental medicine.
[28] T. Niewold. Type I Interferon in Human Autoimmunity , 2014, Front. Immunol..
[29] Haoyang Zhuang,et al. Toll‐like Receptor 7–Stimulated Tumor Necrosis Factor α Causes Bone Marrow Damage in Systemic Lupus Erythematosus , 2014, Arthritis & rheumatology.
[30] L. Ivashkiv,et al. Regulation of type I interferon responses , 2013, Nature Reviews Immunology.
[31] A. Caflisch,et al. Discovery of ZAP70 inhibitors by high-throughput docking into a conformation of its kinase domain generated by molecular dynamics. , 2013, Bioorganic & medicinal chemistry letters.
[32] P. Vidalain,et al. Inhibition of Pyrimidine Biosynthesis Pathway Suppresses Viral Growth through Innate Immunity , 2013, PLoS pathogens.
[33] P. Desprès,et al. Dengue Virus Activates Membrane TRAIL Relocalization and IFN-α Production by Human Plasmacytoid Dendritic Cells In Vitro and In Vivo , 2013, PLoS neglected tropical diseases.
[34] Nouri Neamati,et al. Small Molecule Inhibitors of CXCR4 , 2013, Theranostics.
[35] V. Eraković Haber,et al. Impairment of lysosomal functions by azithromycin and chloroquine contributes to anti-inflammatory phenotype. , 2012, Cellular immunology.
[36] R. Leurs,et al. Pharmacological modulation of chemokine receptor function , 2012, British journal of pharmacology.
[37] VINCENT ZOETE,et al. SwissParam: A fast force field generation tool for small organic molecules , 2011, J. Comput. Chem..
[38] R. Abagyan,et al. Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.
[39] V. Pascual,et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus , 2010, Nature.
[40] A. Nademanee,et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] C. Mohan,et al. Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus , 2009, Expert opinion on therapeutic targets.
[42] P. Igarashi,et al. CXCR4/CXCL12 Hyperexpression Plays a Pivotal Role in the Pathogenesis of Lupus1 , 2009, The Journal of Immunology.
[43] Trixie Wagner,et al. Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo. , 2008, Journal of medicinal chemistry.
[44] V. Pascual,et al. The innate immune system in SLE: type I interferons and dendritic cells , 2008, Lupus.
[45] L. Moldawer,et al. A Novel Type I IFN-Producing Cell Subset in Murine Lupus1 , 2008, The Journal of Immunology.
[46] S. Akira,et al. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. , 2008, Arthritis and rheumatism.
[47] B. Pulendran,et al. Improving Defences at the Portal of HIV Entry: Mucosal and Innate Immunity , 2008, PLoS medicine.
[48] D. Graham,et al. HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-α , 2007, Proceedings of the National Academy of Sciences.
[49] M. Colonna,et al. Crosspresentation: plasmacytoid dendritic cells are in the business. , 2007, Immunity.
[50] Dominique Schols,et al. Molecular Mechanism of Action of Monocyclam Versus Bicyclam Non-peptide Antagonists in the CXCR4 Chemokine Receptor* , 2007, Journal of Biological Chemistry.
[51] V. Pascual,et al. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. , 2006, Immunity.
[52] M. Kruhlak,et al. Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[53] Laxmikant V. Kalé,et al. Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..
[54] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[55] K. Lindblad-Toh,et al. Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammals , 2005, Nature.
[56] J. Lifson,et al. TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. , 2005, Blood.
[57] Shizuo Akira,et al. Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA , 2004, Science.
[58] Mette M. Rosenkilde,et al. Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor , 2004, Journal of Biological Chemistry.
[59] V. Pascual,et al. The central role of dendritic cells and interferon-&agr; in SLE , 2003 .
[60] Persephone Borrow,et al. Viral infection switches non-plasmacytoid dendritic cells into high interferon producers , 2003, Nature.
[61] Virginia Pascual,et al. Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.
[62] N. Kadowaki,et al. Natural type I interferon-producing cells as a link between innate and adaptive immunity. , 2002, Human immunology.
[63] Antonio Lanzavecchia,et al. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells , 2001, European journal of immunology.
[64] L. Nilsson,et al. Structure and Dynamics of the TIP3P, SPC, and SPC/E Water Models at 298 K , 2001 .
[65] R. Skeel,et al. Langevin stabilization of molecular dynamics , 2001 .
[66] S. Akira,et al. A Toll-like receptor recognizes bacterial DNA , 2000, Nature.
[67] T. Witte,et al. Prognostic parameters for flare in systemic lupus erythematosus. , 2000, Rheumatology.
[68] N. Kadowaki,et al. The nature of the principal type 1 interferon-producing cells in human blood. , 1999, Science.
[69] J. Banchereau,et al. The Enigmatic Plasmacytoid T Cells Develop into Dendritic Cells with Interleukin (IL)-3 and CD40-Ligand , 1997, The Journal of experimental medicine.
[70] A. Garg,et al. Type I interferons and dendritic cells in cancer immunotherapy. , 2019, International review of cell and molecular biology.
[71] C. Gordon,et al. Systemic lupus erythematosus , 2016, Nature Reviews Disease Primers.
[72] V. Pascual,et al. The central role of dendritic cells and interferon-alpha in SLE. , 2003, Current opinion in rheumatology.
[73] S. Dzik. The nature of the principal type 1 interferon-producing cells in human blood , 2000 .
[74] J. Moore,et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor , 1998, Nature Medicine.